Post hoc analysis of two phase 3 trials (12,990 patients with CKD and type 2 diabetes): in the 108 with prior nephrectomy, finerenone reduced urine albumin-to-creatinine ratio at 4 months vs placebo (treatment ratio 0.60); hyperkalaemia 7% vs 6%.
Secondary analysisn = 12,990
Munoz Mendoza et al. Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy